Thank you, Mr. Chair.
That was excellent testimony from all of you. Thank you very much.
I'll begin with Ms. Gosselin and Novalait. I want to begin with your funding model, which is something I'm quite familiar with, if I understand correctly, where you're actually having check-offs come from both the processing side and the producing side, and then coming at some agreement around funding models.
With the increased access to the Canadian market through CUSMA, CPTPP and the CETA agreements, are you feeling any of that in your funding model? Are you collecting—I think I know the answer to this question—any check-off on the imports? I think the answer would be no. If it isn't, please inform us. Has there been any other compensation talked about from the research aspect?